A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
Status:
Completed
Trial end date:
2017-07-27
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety of the study drug known as
Prexasertib (LY2606368) in participants with advanced cancer or cancer that has spread to
other parts of the body. This study will involve a single dose of ¹⁴C radiolabelled
Prexasertib . This means that a radioactive substance, carbon 14, will be incorporated into
the study drug. This will provide information about the study drug and its breakdown products
and will help determine how much passes from the blood into urine, feces and expired air.
After a minimum 14-day washout period following the [¹⁴C] Prexasertib dose, participants will
be allowed to receive continued access to Prexasertib as outpatients.